Engineering of the LukS-PV and LukF-PV subunits of Staphylococcus aureus Panton-Valentine leukocidin for Diagnostic and Therapeutic Applications

BMC Biotechnology

Charles Emeka Okolie¹  Alan Cockayne²  Christopher Penfold²  Richard James² 

[1] Department of Biological Sciences, College of Science and Engineering, Landmark University, Omu-Aran, Kwara State, Nigeria

[2] School of Molecular Medical Sciences, Centre for Biomolecular Sciences, University of Nottingham, University Park, Nottingham NG7 2UH, UK

关键词: Immuno-therapy;    Mass spectrometry;    Chromatography;    Leukocytolytic exotoxin;    Panton-Valentine leukocidin;    Staphylococcus aureus;   

Others  :  835078
DOI  :  10.1186/1472-6750-13-103

 received in 2013-09-09, accepted in 2013-10-31,  发布年份 2013

【 摘 要 】

Background

Staphylococcus aureus produces several toxins, including Panton-Valentine leukocidin (PVL). The involvement of PVL in primary skin infections, necrotizing pneumonia, musculoskeletal disorders, brain abscess, and other diseases, some of which are life-threatening, has been reported. Following expert opinion, we aimed to provide the tools for establishment of sequence-based diagnostics and therapeutics for those conditions. We engineered the synergistic S and F (LukS-PV and LukF-PV respectively) pro-toxin subunits from Staphylococcus aureus USA400 into separate expression E. coli BL21(DE3)-pLysS hosts.

Results

Following Nickel affinity chromatography (NAC), the F subunit came out without bands of impurity. The S sub-unit did not come off very pure after NAC thus necessitating further purification by size exclusion and ion-exchange chromatography. The purification plots showed that the BioLogic-LP and AKTA systems are reliable for following the progress of the chromatographic purification in real-time. Computer predicted Mw for the 6His-LukF-PV and 6His-LukS-PV were 35645.41 Da and 33530.04 Da respectively, while the mass spectrometry results were 35643.57 Da and 33528.34 Da respectively.

Conclusion

The BioLogic-LP and AKTA systems are commendable for reliability and user-friendliness. As a recent work elsewhere also reported that a second round of chromatography was necessary to purify the S subunit after the first attempt, we speculate that the S subunit might contain yet unidentified motif(s) requiring further treatment. The purified S and F sub-units of PVL were supplied to the Nottingham Cancer Immunotherapy group who used them to establish sequence-based monoclonal antibodies for diagnostic and therapeutic uses targeting PVL.

【 授权许可】

   
2013 Okolie et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Supersac G, Prevost G, Piemont Y: Sequencing of leucocidin R from Staphylococcus aureus P83 suggests that staphylococcal leucocidins and gamma-hemolysin are members of a single, two-component family of toxins. Infect Immun 1993, 61:580-587.
• [2]Prevost G, Bouakham T, Piemont Y, Monteil H: Characterisation of a synergohymenotropic toxin produced by Staphylococcus intermedius. FEBS Bp 1995a, 376:135-140.
• [3]Kaneko J, Kamio Y: Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci Biotechnol Biochem 2004, 68:981-1003.
• [4]Prevost G, Cribier B, Couppie P, Petiau P, Supersac G, Finck-Barbancon V, et al.: Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities. Infect Immun 1995b, 63:4121-4129.
• [5]Diep BA, Gill SR, Chang RF, Phan TH, Chen JH, Davidson MG, et al.: Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006, 367(9512):731-739.
• [6]Ma XX, Ito T, Kondo Y, Cho M, Yoshizawa Y, Kaneko J, Katai A, Higashiide M, Li S, Hiramatsu K: Two different Panton-Valentine leukocidin phage lineages predominate in Japan. J Clin Microbiol 2008, 46(10):3246-3258.
• [7]Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K-I, Oguchi A, et al.: Genome and virulence determinants of high virulence community-acquired MRSA. The Lancet 2002, 359:1819-1827.
• [8]Hiramatsu K, Watanabe S, Takeuchi F, Ito T, Baba T: Genetic characterization of methicillin-resistant Staphylococcus aureus. Vaccine 2004, 22(1):S5-S8.
• [9]Panton PN, Valentine FCO: Staphylococcal toxin. The Lancet 1932, 219:506-508.
• [10]Hay RJ, Steer AC, Engelman D, Walton S: Scabies in the developing world–its prevalence, complications, and management. Clin Microbiol Infect 2012, 18(4):313-323.
• [11]Prevost G, Couppie P, Prevost P, Gayet S, Petiau P, Cribier B, et al.: Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995, 42:237-245.
• [12]Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter M-O, Gauduchon V, et al.: Involvement of Panton-Valentine alentine leukocidin-producing staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128.
• [13]Schleucher RD, Gaessler M, Knobloch J: Panton-Valentine leukocidin-producing methicillin-sensitive staphylococcus aureus as a cause for recurrent, contagious skin infections in young, healthy travelers returned from a tropical country: a new worldwide public health problem? J Travel Med 2008, 15:137-139.
• [14]Muttaiyah S, Coombs G, Pandey S, Reed P, Ritchie S, Lennon D, et al.: Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New Zealand. J Clin Microbiol 2010, 48(10):3470-3474.
• [15]Jung N, Lehmann C, Hellmann M, Seifert H, Valter MM, Hallek M, et al.: Necrotizing pneumonia caused by Panton-Valentine leucocidin-producing Staphylococcus aureus originating from a Bartholin's abscess. Infect Dis Obstet Gynecol 2008, 2008:491401. doi: 10.1155/2008/491401
• [16]Schefold JC, Esposito F, Storm C, Heuck D, Krüger A, Jörres A, et al.: Therapy-refractory Panton Valentine Leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report. J. Med. Case Reports 2007, 1:165.
• [17]Skov R: Panton-Valentine-leukocidin producing Staphylococcus aureus as the cause of necrotizing pneumonia and death. Ugeskr Laeger 2010, 172(16):1189.
• [18]Rabol PH, Dessau RB, Bjerglund L: Fatal pneumonia with Panton-Valentine leucocidin-producing Staphylococcus aureus. Ugeskr Laeger 2010, 172(16):1190-1191.
• [19]Dubrous P, Cuguillère A, Gendrot A, Koeck JL: Panton-Valentine leukocidin-producing Staphylococcus aureus responsible for necrotizing pneumonia. Ann Biol Clin (Paris) 2007, 65(3):277-281.
• [20]Akpaka PE, Monecke S, Swanston WH, Rao AC, Schulz R, Levett PN: Methicillin sensitive Staphylococcus aureus producing Panton-Valentine leukocidin toxin in Trinidad & Tobago: a case report. J Med Case Rep 2011, 5:157.
• [21]Al-Talib H, Hasan H, Yean CY, Al-Ashwal SM, Ravichandran M: Fatal necrotizing pneumonia caused by Panton-Valentine leukocidin-producing hospital-acquired Staphylococcus aureus: a case report. Jpn J Infect Dis 2011, 64(1):58-60.
• [22]Catena V, Baiocchi M, Lentini P, Badolati L, Baccarin M, Del Monte DD, Rubini A: Necrotizing pneumonia caused by Panton-Valentine leukocidin-producing methicillin-susceptible Staphylococcus aureus (MSSA). Infez Med 2010, 20(3):205-210.
• [23]Rafai M, Abouelalaa K, Skhsoukh Y, Balkhi H, Belyamani L, Dimou M: Evolution of a fatal septic arthritis caused by a Panton-Valentine leukocidin (PVL)-producing Staphylococcus aureus strain. Joint Bone Spine 2013, 80(5):525-527.
• [24]Ramos A, Ley L, Muñez E, Videl A, Sánchez I: Brain abscess due to Panton-Valentine leukocidin-positive Staphylococcus aureus. Infection 2009, 37(4):365-367.
• [25]Enany S, Higuchi W, Okubo T, Takano T, Enany M, Yamamoto T: Brain abscess caused by Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus in Egypt, April 2007. Euro Surveill 2007., 12(39)
• [26]Noah MA, Dawrant M, Faulkner GM, Hill AM, Harvey C, Hussain A, Jenkins DR, Nichani S, Peek GJ, Sosnowski AW, Firmin RK: Panton-Valentine leukocidin expressing Staphylococcus aureus pneumonia managed with extracorporeal membrane oxygenation: experience and outcome. Crit Care Med 2010, 38(11):2250-2253.
• [27]Enany S, Yaoita E, Yoshida Y, Enany M, Yamamoto T: Molecular characterization of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus isolates in Egypt. Microbiol Res 2010, 165(2):152-162.
• [28]Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, Vandenesch F, Etienne J, Lina G: Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 2011, 38(6):457-464.
• [29]Morgan MS: Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia. Int J Antimicrob Agents 2007, 30(4):289-296.
• [30]Morgan M: Staphylococcus aureus, Panton-Valentine leukocidin, and necrotising pneumonia. BMJ 2005, 331:793-794.
• [31]Hooker RS: The treatment of staphylococcus septicaemia by transfusion of immune blood. Ann Surg 1917, 66:513-521.
• [32]Gauduchon V, Cozon G, Vandenesch F, Genestier A-L, Eyssade N, Peyrol S, et al.: Neutralization of staphylococcus aureus Panton valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004, 189:346-353.
• [33]Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: a Laboratory Manual. 2nd edition. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1989.
• [34]Bardelang P, Vankemmelbeke M, Zhang Y, Jarvis H, Antoniadou E, Rochette S, Thomas NR, Penfold CN, James R: Design of a polypeptide FRET substrate that facilitates study of the antimicrobial protease lysostaphin. Biochem J 2009, 418(3):615-624.
• [35]Centers for Disease Control and Prevention and National Institutes of Health: Biosafety in Microbiological and Biomedical Laboratories. 5th edition. Washington: United States Government Printing Office; 2007.
• [36]Chen CC, Hwang JK, Yang JM: (PS)2: Protein structure prediction server. Nuc Acids Res 2006, 34(suppl 2):W152-W157. Available at: http://ps2.life.nctu.edu.tw/ webcite
• [37]Warfield R, Bardelang P, Saunders H, Chan WC, Penfold C, James R, Thomas NR: Internally quenched peptides for the study of lysostaphin: an antimicrobial protease that kills Staphylococcus aureus. Org Biomol Chem 2006, 4:3626-3638.
• [38]Chang V, Ling-Yi C, Wang A, Yuan X: The effect of Lipopolysaccharide core structure defects on transformation efficiency in isogenic Escherichia coli BW25113 rfaG, rfaP, and rfaC mutants. J ExpMicrobiol Immunol (JEMI) 2010, 14:101-107.
• [39]Kuo WH, Chase HA: Exploiting the interactions between poly-histidine fusion tags and immobilized metal ions. Biotechnol Lett 2011, 33(6):1075-1084.
• [40]Kanade RP, Notani NK: Cloning and characterization of a DNA repair gene in Haemophilus influenzae. J Biosci 1987, 12(2):115-123.
• [41]Liu YG, Nagaki K, Fujita M, Kawaura K, Uozumi M, Ogihara Y: Development of an efficient maintenance and screening system for large-insert genomic DNA libraries of hexaploid wheat in a transformation-competent artificial chromosome (TAC) vector. Plant J 2000, 23(5):687-695.
• [42]Graves SF, Kobayashi SD, Braughton KR, Diep BA, Chambers HF, Otto M, et al.: Relative contribution of Panton-Valentine leukocidin to PMN plasma membrane permeability and lysis caused by USA300 and USA400 culture supernatants. Microbes Infect 2010, 12(6):446-456.
• [43]Sriwanthana B, Island MD, Maneval D, Mobley HL: Single-step purification of Proteus mirabilis urease accessory protein UreE, a protein with a naturally occurring histidine tail, by nickel chelate affinity chromatography. J Bacteriol 1994, 176(22):6836-6841.